Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:1:81-6.
doi: 10.2147/dhps.s8495. Epub 2009 Dec 9.

29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections

Stephen Glenski  1 , Jill Conner
Affiliations

29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections

Stephen Glenski et al. Drug Healthc Patient Saf. 2009.

Abstract

Using three surveys, a comparative assessment of needle performance and patient preference for 27-gauge (G) and 29G needles for glatiramer acetate administration for multiple sclerosis therapy was performed. Eligible patients participated in a specialty pharmacy program and administered glatiramer acetate for ≥1 month. In Survey 1 on the 27G needle, 545 (82.70%) patients reported no needle problems, 106 (16.09%) cited one type (dull, bent, or broken), five (0.76%) cited two types, and three (0.46%) cited all three types. In Survey 2 on the 29G needle, 553 (98.05%) indicated no problems, two (0.35%) cited dull needles, and nine (1.60%) cited bent needles. On the 29G needles versus 27G needles pain comparison, 219 (38.83%) reported the 29G needle was a little better, and 155 (27.48%) reported it was a lot better than the 27G. For injection-site experiences, 515 patients (91.31%) reported no, very slight, or mild reactions with the 29G needle. In Survey 3, over 76% of patients preferred the 29G to the 27G needle and significantly fewer patients reported one or more problems with the 29G needle compared to patients reporting problems with the 27G needle (P < 0.00001). In conclusion, significantly fewer patients reported problems after 30 days of use of the 29G than the 27G needle. Fewer injection-site experiences occurred with the 29G needle and the 29G needle was preferred overall.

Keywords: 29 gauge needle; glatiramer acetate; subcutaneous injection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Needle performance data on 27G and 29G needles.
Figure 2
Figure 2
Overall preference for 29G needle relative to the 27G needle.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–1276. - PubMed
    1. Teva Neuroscience Copaxone prescribing information. 2009. Available from: http://www.copaxone.com/. Accessed November 3, 2009.
    1. Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS: Fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245–253. - PubMed
    1. Arnon R, Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit. 2003;16(6):412–421. - PubMed
    1. Weber MS, Prodhomme T, Yossef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007;13(8):935–943. - PubMed